Hideki Iwamoto

5.4k total citations
172 papers, 3.1k citations indexed

About

Hideki Iwamoto is a scholar working on Hepatology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Hideki Iwamoto has authored 172 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Hepatology, 60 papers in Pulmonary and Respiratory Medicine and 55 papers in Surgery. Recurrent topics in Hideki Iwamoto's work include Hepatocellular Carcinoma Treatment and Prognosis (58 papers), Renal cell carcinoma treatment (23 papers) and Prostate Cancer Diagnosis and Treatment (20 papers). Hideki Iwamoto is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (58 papers), Renal cell carcinoma treatment (23 papers) and Prostate Cancer Diagnosis and Treatment (20 papers). Hideki Iwamoto collaborates with scholars based in Japan, Sweden and China. Hideki Iwamoto's co-authors include Takuji Torimura, Hironori Koga, Yihai Cao, Atsushi Takenaka, Yunlong Yang, Sharon Lim, Takashi Niizeki, Shigeo Shimose, Mitsuhiko Abe and Tomotake Shirono and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and The Journal of Experimental Medicine.

In The Last Decade

Hideki Iwamoto

160 papers receiving 3.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hideki Iwamoto Japan	32	1.1k	956	815	706	656	172	3.1k
Bostjan Humar Switzerland	34	1.3k 1.2×	622 0.7×	433 0.5×	576 0.8×	395 0.6×	74	3.0k
Richard D. Kim United States	29	923 0.9×	829 0.9×	653 0.8×	1.7k 2.3×	797 1.2×	198	3.6k
Yohei Masugi Japan	31	857 0.8×	478 0.5×	617 0.8×	1.1k 1.6×	677 1.0×	127	2.9k
Tohru Utsunomiya Japan	37	1.5k 1.4×	1.3k 1.3×	839 1.0×	1.7k 2.4×	607 0.9×	166	4.3k
Asahiro Morishita Japan	29	1.3k 1.2×	565 0.6×	876 1.1×	621 0.9×	434 0.7×	177	2.9k
Tetsuya Ikemoto Japan	34	1.1k 1.0×	861 0.9×	612 0.8×	1.1k 1.6×	498 0.8×	240	3.8k
In‐Sun Chu South Korea	29	2.6k 2.4×	902 0.9×	1.3k 1.6×	980 1.4×	775 1.2×	62	4.4k
Satoru Imura Japan	33	1.1k 1.0×	1.2k 1.2×	591 0.7×	1.2k 1.7×	710 1.1×	255	4.6k
Rongxin Chen China	29	802 0.8×	781 0.8×	592 0.7×	760 1.1×	312 0.5×	114	2.5k
Shinichi Sakamoto Japan	30	1.4k 1.3×	323 0.3×	805 1.0×	545 0.8×	799 1.2×	197	3.3k

Countries citing papers authored by Hideki Iwamoto

Since Specialization

Citations

This map shows the geographic impact of Hideki Iwamoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hideki Iwamoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hideki Iwamoto more than expected).

Fields of papers citing papers by Hideki Iwamoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hideki Iwamoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hideki Iwamoto. The network helps show where Hideki Iwamoto may publish in the future.

Co-authorship network of co-authors of Hideki Iwamoto

This figure shows the co-authorship network connecting the top 25 collaborators of Hideki Iwamoto. A scholar is included among the top collaborators of Hideki Iwamoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hideki Iwamoto. Hideki Iwamoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yamashita, Shimpei, Shuzo Hamamoto, Junya Furukawa, et al.. (2025). Efficacy and Safety of Nivolumab Plus Ipilimumab for Metastatic Renal Cell Carcinoma in Patients 75 Years and Older: Multicenter Retrospective Study. Cancers. 17(3). 474–474.

Shimose, Shigeo, Takashi Niizeki, Hideki Iwamoto, et al.. (2025). Efficacy and safety of lenvatinib‐transcatheter arterial chemoembolization sequential therapy for hepatocellular carcinoma within the up‐to‐seven criteria. Hepatology Research. 55(7). 1015–1025.

Yamashita, Shimpei, Shuzo Hamamoto, Junya Furukawa, et al.. (2024). Association of lung immune prognostic index with survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. Japanese Journal of Clinical Oncology. 54(6). 722–729. 2 indexed citations

Hamamoto, Shuzo, Shimpei Yamashita, Junya Furukawa, et al.. (2024). External validation of hemoglobin and neutrophil levels as predictors of the effectiveness of ipilimumab plus nivolumab for treating renal cell carcinoma. Frontiers in Oncology. 14. 1400041–1400041.

Sakaue, Takahiko, Hironori Koga, Hideki Iwamoto, et al.. (2024). Pancreatic Juice-Derived microRNA-4516 and microRNA-4674 as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma. SHILAP Revista de lepidopterología. 3(6). 761–772. 4 indexed citations

Shimose, Shigeo, Hideki Iwamoto, Masatoshi Tanaka, et al.. (2024). Efficacy of Atezolizumab Plus Bevacizumab–Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma. Current Oncology. 31(10). 5821–5831. 1 indexed citations

Koga, Hironori, Hideki Iwamoto, Hiroyuki Suzuki, et al.. (2023). Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective. Clinical and Molecular Hepatology. 29(2). 242–251. 13 indexed citations

Shimose, Shigeo, Takashi Niizeki, Hideki Iwamoto, et al.. (2023). Telephone follow‐up contributes to improving adherence and treatment duration in patients with hepatocellular carcinoma treated with lenvatinib. Journal of Gastroenterology and Hepatology. 38(7). 1140–1147. 4 indexed citations

Shimose, Shigeo, Hideki Iwamoto, Takashi Niizeki, et al.. (2023). Efficacy of Lenvatinib Combined with Transcatheter Intra-Arterial Therapies for Patients with Advanced-Stage of Hepatocellular Carcinoma: A Propensity Score Matching. International Journal of Molecular Sciences. 24(18). 13715–13715. 4 indexed citations

10.

Shimose, Shigeo, Hideki Iwamoto, Tomotake Shirono, et al.. (2023). The impact of curative conversion therapy aimed at a cancer‐free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Cancer Medicine. 12(11). 12325–12335. 14 indexed citations

11.

Suzuki, Hiroyuki, Toshimitsu Tanaka, Hideki Iwamoto, et al.. (2023). Safety of Early Bevacizumab Administration after Central Venous Port Placement for Patients with Colorectal Cancer. Cancers. 15(8). 2264–2264. 1 indexed citations

12.

Honda, Masashi, et al.. (2022). Incidence and predictive factors of orgasmic dysfunction after robot‐assisted radical prostatectomy: A cross‐sectional, questionnaire‐based study. International Journal of Urology. 29(11). 1304–1309. 2 indexed citations

13.

Nakano, Masahito, Kazuta Fukumori, Yoichi Yano, et al.. (2021). Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. Cancers. 13(21). 5282–5282. 12 indexed citations

14.

Shirono, Tomotake, Hironori Koga, Takashi Niizeki, et al.. (2021). Usefulness of a novel transarterial chemoinfusion plus external‐beam radiation therapy for advanced hepatocellular carcinoma with tumor thrombi in the inferior vena cava and right atrium: Case study. Cancer Reports. 5(8). e1539–e1539. 5 indexed citations

15.

Kamachi, Naoki, Masahito Nakano, Shusuke Okamura, et al.. (2021). Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast‐enhanced ultrasound. Cancer Reports. 5(2). e1471–e1471. 6 indexed citations

16.

Iwamoto, Hideki, Shigeo Shimose, Yu Noda, et al.. (2021). Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice. Cancers. 13(11). 2786–2786. 39 indexed citations

17.

Nakano, Masahito, Ryoko Kuromatsu, Takashi Niizeki, et al.. (2020). Primary Treatment with Molecular‐Targeted Agents for Hepatocellular Carcinoma: A Propensity Score‐matching Analysis. Hepatology Communications. 4(8). 1218–1228. 18 indexed citations

18.

Honda, Masashi, Yusuke Kimura, Hideki Iwamoto, et al.. (2019). Longitudinal study on the impact of urinary continence and sexual function on health‐related quality of life among Japanese men after robot‐assisted radical prostatectomy. International Journal of Medical Robotics and Computer Assisted Surgery. 15(4). e2018–e2018. 8 indexed citations

19.

Koga, Hironori, Jun Akiba, Mitsuhiko Abe, et al.. (2017). Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1. Molecular Cancer Research. 15(6). 744–752. 32 indexed citations

20.

Inoue, Kinya, Takuji Torimura, Tõru Nakamura, et al.. (2012). Vandetanib, an Inhibitor of VEGF Receptor-2 and EGF Receptor, Suppresses Tumor Development and Improves Prognosis of Liver Cancer in Mice. Clinical Cancer Research. 18(14). 3924–3933. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact